Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Wyeth Effexor XR Detail Will Add 120 Reps Mid-Year Under Solvay Deal

  • News

Executive Summary

Solvay's mental health sales force will detail Wyeth's antidepressant Effexor XR (venlafaxine) starting mid-year under a co-promotion deal announced April 1

You may also be interested in...



Solvay Picks Up Tricor Franchise Through Acquisition Of Fournier Pharma

Solvay plans to continue working with Abbott on the Tricor franchise in the U.S. after acquiring Fournier Pharma

Solvay Picks Up Tricor Franchise Through Acquisition Of Fournier Pharma

Solvay plans to continue working with Abbott on the Tricor franchise in the U.S. after acquiring Fournier Pharma

Forest Expects Lexapro To Gain Market Share Despite Lilly Cymbalta Launch

Forest is expecting continued market share gains for Lexapro as it prepares for the upcoming launch of Lilly's antidepressant Cymbalta

Table

View full table

Tags:
Latest Headlines

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications

Industry & Regulators To Align Advice on COVID-19 Vaccine Updates

Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines

See All
UsernamePublicRestriction

Register

PS043695

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By